➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
Baxter
Boehringer Ingelheim
McKinsey

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Methyl beta-galactoside

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Methyl beta-galactoside?

Methyl beta-galactoside is an investigational drug.

There have been 17 clinical trials for Methyl beta-galactoside. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Aphasia, Broca, Brain Neoplasms, and Vascular Diseases. The leading clinical trial sponsors are University of Southern California, National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI).

There are one hundred and thirty-two US patents protecting this investigational drug and nine hundred and seventy-four international patents.

Recent Clinical Trials for Methyl beta-galactoside
TitleSponsorPhase
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesNational Cancer Institute (NCI)Early Phase 1
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesUniversity of Southern CaliforniaEarly Phase 1
Prolotherapy Versus Cortisone Injections for Partial Rotator Cuff TearsHadassah Medical OrganizationPhase 2

See all Methyl beta-galactoside clinical trials

Clinical Trial Summary for Methyl beta-galactoside

Top disease conditions for Methyl beta-galactoside
Top clinical trial sponsors for Methyl beta-galactoside

See all Methyl beta-galactoside clinical trials

US Patents for Methyl beta-galactoside

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Methyl beta-galactoside   Get Started for $10 Multifunctional (meth)acrylate manufacturing method TOAGOSEI CO., LTD. (Tokyo, JP)   Get Started for $10
Methyl beta-galactoside   Get Started for $10 Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR Pfizer Inc. (New York, NY)   Get Started for $10
Methyl beta-galactoside   Get Started for $10 Method for producing (meth)acrylate TOAGOSEI CO., LTD (Tokyo, JP)   Get Started for $10
Methyl beta-galactoside   Get Started for $10 Network-based microbial compositions and methods Seres Therapeutics, Inc. (Cambridge, MA)   Get Started for $10
Methyl beta-galactoside   Get Started for $10 Self-repairing polyurethane networks Clemson University (Clemson, SC)   Get Started for $10
Methyl beta-galactoside   Get Started for $10 Glycoclusters and their pharmaceutical use as antibacterials CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE DE MONTPELLIER 1 (Montpellier, FR)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Methyl beta-galactoside

Drugname Country Document Number Estimated Expiration Related US Patent
Methyl beta-galactoside China CN106029628 2034-04-16   Get Started for $10
Methyl beta-galactoside European Patent Office EP3133058 2034-04-16   Get Started for $10
Methyl beta-galactoside Japan JP6273539 2034-04-16   Get Started for $10
Methyl beta-galactoside Japan JPWO2015159611 2034-04-16   Get Started for $10
Methyl beta-galactoside South Korea KR20160148514 2034-04-16   Get Started for $10
Methyl beta-galactoside World Intellectual Property Organization (WIPO) WO2015159611 2034-04-16   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
McKinsey
Harvard Business School
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.